Trial reportPloS one2017
Randomized clinical trial to evaluate the effect of fecal microbiota transplant for initial Clostridium difficile infection in intestinal microbiome.
Trial report in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05709184 (Lyophilized Fecal Microbiome Transfer for Primary Clostridioides Difficile Infection), which is not on this map. Cited by 21 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Lyophilized Fecal Microbiome Transfer for Primary Clostridioides Difficile Infection (DONATE Study): a Multicenter Randomized Controlled Trial
Who cites it
21 citing papers in PubMed, 3 syntheses or guidelines pooled it, 54 citations in OpenAlex.
- Safety and efficacy of fecal microbiota transplantation versus antibiotics for treating clostridioides difficile infection: systematic review and meta-analysis.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Pooled it
- Comparing the efficacy and safety of faecal microbiota transplantation with bezlotoxumab in reducing the risk of recurrentBMJ open · 2019Pooled it
- Pooled it
- Fecal Microbiota Transplantation in 2025: Two Steps Forward, One Step Back.Current gastroenterology reports · 2026Review
- Comparative effectiveness of different therapies forThe Lancet regional health. Europe · 2025Article
- Protective effects of fecal microbiota transplantation against ischemic stroke and other neurological disorders: an update.Frontiers in immunology · 2024Review
- Clostridioides Difficile in Latin America: An Epidemiological Overview.Current microbiology · 2023Review
- Clinical Practice Guidelines for Fecal Microbiota Transplantation in Korea.Journal of neurogastroenterology and motility · 2022Review
- Research trends on clinical fecal microbiota transplantation: A biliometric analysis from 2001 to 2021.Frontiers in immunology · 2022Article
- Feature selection and causal analysis for microbiome studies in the presence of confounding using standardization.BMC bioinformatics · 2021Article
- Application of Microbiome Management in Therapy forPathogens (Basel, Switzerland) · 2021Review
- Article
- Fecal microbiota transplants: A review of emerging clinical data on applications, efficacy, and risks (2015-2020).Qatar medical journal · 2021Article
- South African Society of Clinical MicrobiologySouthern African journal of infectious diseases · 2020Article
- Fecal microbiota transplantation beyond Clostridioides difficile infections.EBioMedicine · 2019Review
- Gut integrity in critical illness.Journal of intensive care · 2019Review
- Fecal microbiota transplantation: great potential with many challenges.Translational gastroenterology and hepatology · 2019Review
- The Effect of Gluten-Free Diet on Health and the Gut Microbiota Cannot Be Extrapolated from One Population to Others.Nutrients · 2018Review
- Adverse events in fecal microbiota transplantation: a systematic review and meta-analysis.Annals of gastroenterologyArticle
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe aim of this study was to evaluate the impact of fecal donor-unrelated donor mix (FMT-FURM) transplantation as first-line therapy for C. difficile infection (CDI) in intestinal microbiome.
methodsWe designed an open, two-arm pilot study with oral vancomycin (250mg every 6 h for 10-14 days) or FMT-FURM as treatments for the first CDI episode in hospitalized adult patients in Hospital Universitario "Dr. Jose Eleuterio Gonzalez". Patients were randomized by a closed envelope method in a 1: 1 ratio to either oral vancomycin or FMT-FURM. CDI resolution was considered when there was a reduction on the Bristol scale of at least 2 points, a reduction of at least 50% in the number of bowel movements, absence of fever, and resolution of abdominal pain (at least two criteria). From each patient, a fecal sample was obtained at days 0, 3, and 7 after treatment. Specimens were cultured to isolate C. difficile, and isolates were characterized by PCR. Susceptibility testing of isolates was performed using the agar dilution method. Fecal samples and FMT-FURM were analyzed by 16S rRNA sequencing.
resultsWe included 19 patients; 10 in the vancomycin arm and 9 in the FMT-FURM arm. However, one of the patients in the vancomycin arm and two patients in the FMT-FURM arm were eliminated. Symptoms resolved in 8/9 patients (88.9%) in the vancomycin group, while symptoms resolved in 4/7 patients (57.1%) after the first FMT-FURM dose (P = 0.26) and in 5/7 patients (71.4%) after the second dose (P = 0.55). During the study, no adverse effects attributable to FMT-FURM were observed in patients. Twelve isolates were recovered, most isolates carried tcdB, tcdA, cdtA, and cdtB, with an 18-bp deletion in tcdC. All isolates were resistant to ciprofloxacin and moxifloxacin but susceptible to metronidazole, linezolid, fidaxomicin, and tetracycline. In the FMT-FURM group, the bacterial composition was dominated by Firmicutes, Bacteroidetes, and Proteobacteria at all-time points and the microbiota were remarkably stable over time. The vancomycin group showed a very different pattern of the microbial composition when comparing to the FMT-FURM group over time.
conclusionThe results of this preliminary study showed that FMT-FURM for initial CDI is associated with specific bacterial communities that do not resemble the donors' sample.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.